Literature DB >> 18828980

Contemporary pacemakers: what the primary care physician needs to know.

Karoly Kaszala1, Jose F Huizar, Kenneth A Ellenbogen.   

Abstract

Pacemaker therapy is most commonly initiated because of symptomatic bradycardia, usually resulting from sinus node disease. Randomized multicenter trials assessing the relative benefits of different pacing modes have made possible an evidence-based approach to the treatment of bradyarrhythmias. During the past several decades, major advances in technology and in our understanding of cardiac pathophysiology have led to the development of new pacing techniques for the treatment of heart failure in the absence of bradycardia. Left ventricular or biventricular pacing may improve symptoms of heart failure and objective measurements of left ventricular systolic dysfunction by resynchronizing cardiac contraction. However, emerging clinical data suggest that long-term right ventricular apical pacing may have harmful effects. As the complexity of cardiac pacing devices continues to grow, physicians need to have a basic understanding of device indications, device function, and common problems encountered by patients with devices in the medical and home environment.

Entities:  

Mesh:

Year:  2008        PMID: 18828980     DOI: 10.4065/83.10.1170

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  3 in total

1.  Fast and furious: new ways to think about, study and treat cardiac arrhythmias.

Authors:  Michael J Joyner; Stanley Nattel
Journal:  J Physiol       Date:  2009-04-01       Impact factor: 5.182

2.  The business of providing high-quality content to Mayo Clinic Proceedings' readers: 2009 and beyond.

Authors:  William L Lanier
Journal:  Mayo Clin Proc       Date:  2009       Impact factor: 7.616

3.  The prevalence and contents of advance directives in patients with pacemakers.

Authors:  Dario Pasalic; Tanya H Tajouri; Abigale L Ottenberg; Paul S Mueller
Journal:  Pacing Clin Electrophysiol       Date:  2013-11-11       Impact factor: 1.976

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.